Synonyms: example 16a [US8685993] | VPS34-IN1
Compound class:
Synthetic organic
Comment: An inhibitor of the lipid kinase VPS34 (PIK3C3). VPS34-IN-1 is claimed as example 16a in patent US8685993 [1], which suggests that VPS34 inhibitors could be of use in treating hyperproliferative diseases characterized by hyperactivity of Vps34.
SARS-CoV-2: VPS34-IN-1 has been used in vitro to establish that VPS34 is required for SARS-CoV-2 replication [2]. ![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Taracido IC, Harrington EM, Honda A, Keaney E. (2014)
Bi-heteroaryl compounds as Vps34 inhibitors. Patent number: US8685993. Assignee: Novartis Ag. Priority date: 21/12/2010. Publication date: 01/04/2014. |
2. Williams CG, Jureka AS, Silvas JA, Nicolini AM, Chvatal SA, Carlson-Stevermer J, Oki J, Holden K, Basler CF. (2021)
Inhibitors of VPS34 and fatty-acid metabolism suppress SARS-CoV-2 replication. Cell Rep, 36 (5): 109479. [PMID:34320401] |